Robert J. Perez, former Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joined its Board of Directors at Flex Pharma, a biotech which is developing therapies for exercise associate muscle cramps, nocturnal leg cramps, an neuromuscular related spasms.
Mr. Perez joined Cubist in 2003, as Senior Vice President, Sales and Marketing and led the launch of Cubicin® (daptomycin for injection). He served as Executive Vice President and Chief Operating Officer (COO) for the company from 2007 to 2012 and President and COO from 2012 to 2014. He currently serves on the Board of Directors of AMAG Pharmaceuticals and Cidara Therapeutics.
“With significant growth opportunities for both the consumer and pharmaceutical arms of the business, I am excited to join the Flex Pharma Board since the Company is uniquely positioned to help a wide range of individuals – from athletes to patients – who suffer from cramps and spasms,” said Rob Perez.
“I’ve long admired Rob as a thought leader in the biotech community and we are gratified to have his experience successfully transforming a pre-commercial biotechnology company into a commercial organization as Flex Pharma grows to become a leading neuromuscular company,” commented Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer of Flex Pharma.
Also on the Board of Directors of Flex Pharma are Rod MacKinnon, M.D., Nobel Laureate and scientific co-founder; John Sculley, former Apple CEO and PepsiCo CEO; Peter Barton Hutt, former General Counsel of the U.S. Food and Drug Administration; Marc Kozin, Senior Advisor to L.E.K. Consulting; Stuart Randle, former CEO of GI Dynamics; Jeffrey Capello, former CFO of Ortho-Clinical Diagnostics and Boston Scientific; and Dr. Westphal, Chairman and Chief Executive Officer of Flex Pharma.